Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29013071 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL25765834 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL2960161 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL24411299 | 0.92 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL142417 | 0.92 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL375444 | 0.92 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL144302 | 0.92 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL12979137 | 0.92 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL29013041 | 0.90 | ALDH1A1 (0.40) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL29013072 | 0.90 | ALDH1A1 (0.40) | ALDH1A1HSD17B10TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | ALDH1A1 1002/4885HSD17B10 209/4885TSHR 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.